Advertisement

Topics

Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes

08:00 EST 6 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA® (sitagliptin) or Metformin Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (N...

Other Sources for this Article

Merck Media:
Doris Li, (908) 246-5701
or
Merck Investor:
Amy Klug, (908) 740-1898
or
Kristen Drake, (908) 236-4223
or
Pfizer Media:
Steve Danehy, (212) 733-1538
or
Pfizer Investor:
Ryan Crowe, (212) 733-8160

NEXT ARTICLE

More From BioPortfolio on "Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes"

Advertisement
Quick Search
Advertisement
Advertisement